🇨🇦·1d agoIndustry
Bausch Health, Canada Inc. et l’Alliance pancanadienne pharmaceutique concluent avec succès leurs négociations, menant à la signature d’une lettre d’intention pour OKEDI MC (suspension injectable à libération prolongée de rispéridone) dans le traitement de la schizophrénie
Publisher
B
Bausch Health (IR News)
Canada
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on ir.bauschhealth.com
Leave the platform to read the original full article on the publisher site.
Source: Bausch Health (IR News)
Scope: Industry
Related coverage
More related coverage
SELLAS Life Sciences·4h ago
Company - Sellas Life Sciences
Hyman, Phelps & McNamara (FDA Law)·6h ago
WuXi AppTec’s 1260H Listing Brings the BIOSECURE Act Back to Center Stage
Sumitomo Pharma·12h ago
Update on Patient Enrollment in Phase 2 Study of Enzomenib for Acute Leukemia
Menicon·14h ago